Abstract:Background: Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. Bcr-Abl-T315I is the notorious point mutation that causes resistance to imatinib and the second generation tyrosine kinase inhibitors, leading to poor prognosis. CML blasts have constitutive p65 (RelA NF-kappa B) transcriptional activity, and NF-kappa B may be a potential target for molecular therapies in CML that may also be effective against CML cells with Bcr-Abl-T315I.Results: In this report, we discovered that pristimerin, a quinonemethide triterpenoid isolated from Celastraceae and Hippocrateaceae, inhibited growth and induced apoptosis in CML cells, including the cells harboring Bcr-Abl-T315I mutation. Additionally, pristimerin inhibited the growth of imatinib-resistant Bcr-Abl-T315I xenografts in nude mice. Pristimerin blocked the TNF alpha-induced I kappa B alpha phosphorylation, translocation of p65, and expression of NF-kappa B-regulated genes. Pristimerin inhibited two steps in NF-kappa B signaling: TAK1TIKK and IKKTI kappa B alpha. Pristimerin potently inhibited two pairs of CML cell lines (KBM5 versus KBM5-T315I, 32D-Bcr-Abl versus 32D-Bcr-Abl-T315I) and primary cells from a CML patient with acquired resistance to imatinib. The mRNA and protein levels of Bcr-Abl in imatinib-sensitive (KBM5) or imatinib-resistant (KBM5-T315I) CML cells were reduced after pristimerin treatment. Further, inactivation of Bcr-Abl by imatinib pretreatment did not abrogate the TNFa-induced NF-kappa B activation while silencing p65 by siRNA did not affect the levels of Bcr-Abl, both results together indicating that NF-kappa B inactivation and Bcr-Abl inhibition may be parallel independent pathways.Conclusion: To our knowledge, this is the first report to show that pristimerin is effective in vitro and in vivo against CML cells, including those with the T315I mutation. The mechanisms may involve inhibition of NF-kappa B and Bcr-Abl. We concluded that pristimerin could be a lead compound for further drug development to overcome imatinib resistance in CML patients.

Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation

Simvastatin Preferentially Targets FLT3 /ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways

CAY10683 and Imatinib Have Synergistic Effects in Overcoming Imatinib Resistance Via HDAC2 Inhibition in Chronic Myeloid Leukemia.

Stromal Cells Attenuate the Cytotoxicity of Imatinib on Philadelphia Chromosome-Positive Leukemia Cells by Up-Regulating the VE-cadherin/β-catenin Signal

C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells

CX‑5461 Potentiates Imatinib‑induced Apoptosis in K562 Cells by Stimulating KIF1B Expression.

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins

Inhibition of Proliferation and Induction of Apoptosis by Simvastatin in K562 Le Ukemic Cell Line

Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.

Synergy Between Proteasome Inhibitors And Imatinib Mesylate In Chronic Myeloid Leukemia

The potentiation of menadione on imatinib by down-regulation of ABCB1 expression.

Spautin-1, a Novel Autophagy Inhibitor, Enhances Imatinib-Induced Apoptosis in Chronic Myeloid Leukemia

SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Proteasome Inhibitor/Imatinib Combinations Exert Potentiated Antileukemia Efficacy But Not Cardiotoxicity In Chronic Myeloid Leukemia

Combining Nilotinib And Imatinib Improves The Outcome Of Imatinib-Resistant Blast Phase Cml

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.

MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy

Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia

Pristimerin Induces Apoptosis In Imatinib-Resistant Chronic Myelogenous Leukemia Cells Harboring T315i Mutation By Blocking Nf-Kappa B Signaling And Depleting Bcr-Abl

Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy

Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.